Detailed Narrative
Strong Q1 FY27 Performance Exceeds Guidance
Metropolis Healthcare reported a robust start to FY27, with revenue growing 17% year-on-year to INR 450 crores, surpassing its stated guidance. This growth was primarily volume-driven, with patient volumes increasing by 10% and test volumes by 11%. The company's EBITDA margin expanded by 210 basis points to 25.2%, reaching INR 113 crores, while PAT grew 26% year-on-year to INR 57 crores, with a PAT margin of 12.6%.
Strategic Segments and North India Expansion Drive Growth
Both B2C and B2B segments demonstrated strong performance, growing 18% and 15% respectively. The strategic TruHealth portfolio grew 22% year-on-year, contributing 18% to Q1 revenue, while Specialty Diagnostics grew 17%, accounting for 40% of revenue. North India emerged as a key growth region, with revenue increasing 19% year-on-year and now contributing 18% to overall revenue, up from a single-digit contribution prior to recent acquisitions.
Disciplined Network Expansion and Efficiency Gains
The company added 300 centers in Q1 FY27 and remains on track to add over 500 centers for the full financial year, targeting 400-500 centers in Tier-2 and Tier-3 towns. Metropolis operates across 750 towns, with its center-to-laboratory ratio improving from 1:21 a year ago to 1:24 in Q1, aiming for 1:30 by year-end. This expansion is data-driven, focusing on underserved markets and improving operating leverage.
Core Diagnostics Integration and Margin Trajectory
Core Diagnostics is in the final stages of integration, with management noting an effective acquisition multiple of approximately 10x EBITDA based on FY27 projections. The company aims to improve Core Diagnostics' EBITDA margin from its current high single-digit (approximately 8% last quarter) to 25% within 3-4 years of acquisition. Other recent acquisitions, including DAPIC Dehradun and Scientific Pathology, Agra, are fully integrated and performing ahead of expectations.
Focus on Quality, Technology, and Specialty Testing
Metropolis continues to differentiate itself through quality, evidenced by a 99% EQAS score and 99.99% report accuracy. The company added 36 new tests in Q1, building on 347 additions in FY26, strengthening its high-value Specialty categories. Investments in digital platforms, automation, and AI are enhancing customer engagement, lab efficiency, and overall operational model, with a clear focus on data governance and patient privacy.
FY27 Outlook and Capital Allocation Strategy
Metropolis maintains its FY27 revenue growth guidance of 14%-15%, primarily driven by volume growth (9%-10%) and product mix. The company targets an EBITDA margin of 27%-28% for FY27 and the next year, expecting a 100-150 basis point improvement this year through operational efficiencies. Capex for FY27 is projected to be similar to last year's INR 65 crores. The M&A strategy remains focused on bolt-on acquisitions of strong brands with ethical practices and positive unit economics, open to larger EPS-accretive deals at fair valuations.